AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 29660425
Drug: Certolizumab 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certolizumab 400 mg every 2 weeks for 16 weeks
Trial: 29660425
Drug: Certolizumab 200
RxNorm normalized name: certolizumab 200 mg subcutaneous kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Certolizumab 200 mg every 2 weeks for 16 weeks
Trial: 21846661
Drug: Selegiline transdermal
RxNorm normalized name: Selegiline Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selegiline transdermal system (STS) with brief repeated behavioral intervention (BRBI)
Trial: 21846661
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch with brief repeated behavioral intervention (BRBI)
Trial: 20671013
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements (≥500 mg/day)
Trial: 18209721
Drug: DNAemia cutoff
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNAemia cutoff of 10,000 copies per ml whole blood
Trial: 18209721
Drug: Antigenemia positivity
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigenemia positivity for initiation of preemptive therapy
Trial: 12556541
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (multifactorial intervention targeting hyperglycemia, hypertension, dyslipidemia, and microalbuminuria, along with secondary prevention with aspirin)
Trial: 10644551
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion at 6 mg x kg(‐1) x min(‐1)
Trial: 10644551
Drug: Glucose infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose infusion at 2 mg x kg(‐1) x min(‐1)
Trial: 10644551
Drug: Glucose pulse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose pulse induction (6 mg x kg(‐1) x min(‐1))
Trial: 1653671
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (320 fmol/min)
Trial: 11521984
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg bid for 4 weeks
Trial: 6301262
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg bid for up to 8 weeks (after initial 4 weeks of placebo for unhealed patients)
Trial: 27480499
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination (DRE) posterior surface area estimates
Trial: 25370155
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment for 4 weeks
Trial: 23288881
Drug: Ezetimibe/simvastatin (EZ/S)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin (EZ/S) 10/20 mg
Trial: 23288881
Drug: Doubling the
RxNorm normalized name: THE-630
DrugBank: THE-630 (DB16750)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg)
Trial: 23288881
Drug: Switching to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switching to rosuvastatin 10 mg
Trial: 14996137
Drug: Lamotrigine (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lamotrigine (long-term treatment)
Trial: 14996137
Drug: Risperidone (short-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (short-term treatment)
Trial: 14996137
Drug: Divalproex (short-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divalproex (short-term treatment)
Trial: 14996137
Drug: Fluoxetine (short-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluoxetine (short-term treatment)
Trial: 14996137
Drug: Venlafaxine (short-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venlafaxine (short-term treatment)
Trial: 14996137
Drug: Lithium (long-term
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (long-term treatment)
Trial: 12575569
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine (CHM) plus bronchial arterial infusion chemotherapy (BAIC)
Trial: 12575569
Drug: Bronchial arterial
RxNorm normalized name: Bronchitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bronchial arterial infusion chemotherapy (BAIC) alone
Trial: 3243913
Drug: Single 16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 16 mg dose
Trial: 3243913
Drug: 1.6 mg
RxNorm normalized name: menthol 1.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg dose given hourly for 10 doses
Trial: 3243913
Drug: Initial dose
RxNorm normalized name: PEANUT ALLER INITIAL DOSE ORAL,PKT,13
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 4.8 mg, followed by 1.6 mg doses given every hour for seven additional doses
Trial: 3243913
Drug: Dosing regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing regimen 1
Trial: 3243913
Drug: Dosing regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing regimen 2
Trial: 3243913
Drug: Dosing regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing regimen 3
Trial: 30626409
Drug: High-dose intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intramuscular scopolamine augmentation
Trial: 30626409
Drug: Low-dose intramuscular
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose intramuscular scopolamine augmentation
Trial: 25796459
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Brentuximab vedotin (1.8 mg/kg, 16 cycles, IV every 3 weeks)
Trial: 16964670
Drug: Recombinant hepatitis
RxNorm normalized name: Recombinant hepatitis B human immunoglobulin
DrugBank: Lenvervimab (DB17814)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant hepatitis B vaccine (Engerix‐B SKB 20 microg) administered according to a 0, 1, 2 month regime.
Trial: 11111813
Drug: Biseko (standardized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biseko (standardized serum protein solution)
Trial: 8329259
Drug: propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol 2.5 mg kg‐1
Trial: 8329259
Drug: thiopentone 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: thiopentone 5.0 mg kg‐1
Trial: 10642369
Drug: Creatine (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine (5 g Cr monohydrate + 20 g glucose) four times per day for 5 days
Trial: 8697183
Drug: 10 mL
RxNorm normalized name: Vial Empty 10 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mL bolus of any solution
Trial: 7971477
Drug: Tris (pH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tris (pH = 10.5) intravenous infusion followed by hyperventilation
Trial: 3653415
Drug: Mifepristone 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 25 mg bid for 7 days
Trial: 3653415
Drug: Mifepristone 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone 50 mg bid for 7 days
Trial: 3653415
Drug: Epostane 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epostane 200 mg qid for 7 days
Trial: 23953888
Drug: Isotretinoin-Lidose formulation
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin-Lidose formulation
Trial: 23953888
Drug: Innovator isotretinoin
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Innovator isotretinoin formulation
Trial: 21156983
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 15 mL each of bupivacaine 0.5% and mepivacaine 1.5%
Trial: 10638351
Drug: EEG biofeedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EEG biofeedback treatment
Trial: 10768305
Drug: Topiramate (TPM)
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate (TPM) in dosages of 100‐1,600 mg/day
Trial: 749854
Drug: Carbenoxolone plus
RxNorm normalized name: carbenoxolone
DrugBank: Carbenoxolone (DB02329)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbenoxolone plus antacids (CBX + AA)
Trial: 31279962
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (CTX) 50 mg daily (Arm A)
Trial: 31279962
Drug: Oral cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cyclophosphamide (CTX) 50 mg daily with celecoxib 400 mg twice daily (Arm B)
Trial: 26611120
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (Nutraceuticals + Ezetimibe)
Trial: 19539099
Drug: ramipril 5
RxNorm normalized name: ramipril 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 5 mg/d (low-dose group)
Trial: 19539099
Drug: ramipril 10
RxNorm normalized name: ramipril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril 10 mg/d (high-dose group)
Trial: 19539099
Drug: ramipril (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ramipril (both formulations)
Trial: 16432050
Drug: Chlorthalidone 12.5
RxNorm normalized name: chlorthalidone 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone 12.5 mg/day
Trial: 11560454
Drug: Intravenous itraconazole
RxNorm normalized name: Itraconazole
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous itraconazole followed by oral itraconazole solution
Trial: 11915854
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg/day
Trial: 9158080
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg + MPA 2.5 mg/day
Trial: 9158080
Drug: CEE 0.31
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.31 mg + MPA 2.5 mg/day
Trial: 9158080
Drug: CEE 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE 0.625 mg alone or with MPA
Trial: 19169336
Drug: Selenium and
RxNorm normalized name: Selenium and/or selenium compound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selenium and aspirin (SAM)
Trial: 10746892
Drug: Standardized soy
RxNorm normalized name: soy acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized soy extract (SOYSELECT) 400 mg/day
Trial: 10390097
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogens (CEE) 0.625 mg/day
Trial: 8777352
Drug: Intracytoplasmic sperm
RxNorm normalized name: herring sperm DNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracytoplasmic sperm injection (ICSI); 127 metaphase II oocytes injected.
Trial: 29343012
Drug: Individualized treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized treatment regimen (2SHRZE/6HRE) with drug replacement based on DST results, treatment duration of 12 months or more if drug resistance is present, otherwise 8 months standard treatment.
Trial: 29343012
Drug: Intensified retreatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified retreatment regimen (2HL(2)EZS/2HL(2)EZS(3)/4HL(2)E) with specific dosing based on body weight, total treatment duration of 8 months.
Trial: 29343012
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment regimen (2HREZS/6HRE) recommended by national tuberculosis program, total treatment duration of 8 months.
Trial: 16616557
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg vitamin C and 400 IU vitamin E daily from the second trimester until delivery
Trial: 16616557
Drug: Matched placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo daily from the second trimester until delivery
Trial: 11783744
Drug: l‐alpha‐acetylmethadol (LAAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐alpha‐acetylmethadol (LAAM)
Trial: 8293297
Drug: Oral inositol
RxNorm normalized name: Inositol
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral inositol treatment
Trial: 3318427
Drug: Nabumetone 1,000
RxNorm normalized name: nabumetone 1,000 mg ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabumetone 1,000 mg per day at bedtime
Trial: 27809345
Drug: Nebilet HCT™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebilet HCT™ (nebivolol 5 mg + hydrochlorothiazide 12.5 mg tablet)
Trial: 27809345
Drug: Nebilet™ (nebivolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebilet™ (nebivolol 5 mg tablet)
Trial: 27809345
Drug: Clorana™ (hydrochlorothiazide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clorana™ (hydrochlorothiazide 25 mg tablet)
Trial: 26229445
Drug: Paracetamol (APAP)
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol (APAP)
Trial: 23258770
Drug: Non-anti-angiogenic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-anti-angiogenic therapy (TACE)
Trial: 17497441
Drug: 80 microg
RxNorm normalized name: Folic acid 80 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 microg intradermal (ID) vaccination
Trial: 17497441
Drug: 160 microg
RxNorm normalized name: Glycopyrronium (as glycopyrrolate) 160 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 160 microg intramuscular (IM) vaccination
Trial: 7709991
Drug: Salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol 50 micrograms twice a day
Trial: 3593906
Drug: Ciramadol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciramadol (30 mg) administered in a fasting state
Trial: 3593906
Drug: Ciramadol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciramadol (30 mg) administered in a postprandial state
Trial: 29334874
Drug: Telemedicine‐Enhanced Antidepressant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telemedicine‐Enhanced Antidepressant Management intervention delivered in VA community‐based outpatient clinics (CBOCs)
Trial: 1355595
Drug: Metoprolol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol therapy
Trial: 23921199
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow oxygen therapy (NHF) at 45 litre min(‐1)
Trial: 23921199
Drug: Nasal high-flow
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal high-flow oxygen therapy (NHF)
Trial: 21914365
Drug: salmeterol/fluticasone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol/fluticasone (50 µg/500 µg)
Trial: 21914365
Drug: salbutamol/ipratropium bromide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salbutamol/ipratropium bromide (120 µg/21 µg)
Trial: 18344725
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole (starting dose 5 mg/d, mean end-point dose of 11.0 mg/d)
Trial: 11739305
Drug: Muscarinic receptor
RxNorm normalized name: Muscarinic receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Muscarinic receptor density measurement using PET with (11)C‐MQNB
Trial: 11739305
Drug: Heart rate
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heart rate (HR) response to intravenous infusion of isoproterenol (5 minutes after 2 mg of atropine, 5, 10, and 15 ng/kg per minute during 5 minutes per step)
Trial: 8390240
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose (25 mg) of naltrexone
Trial: 8390240
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose (100 mg) of naltrexone
Trial: 8390240
Drug: Naltrexone (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (both doses)
Trial: 3080221
Drug: FUDR 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FUDR 0.3 mg/kg/day for 2 weeks, mitomycin C 15 mg/m2 over 1 hour every 8 weeks, BCNU 150 mg/m2 over 1 hour every 8 weeks via hepatic artery
Trial: 3080221
Drug: Single-agent FUDR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent FUDR (planned for future randomized trial)
Trial: 29104132
Drug: Adalimumab in
RxNorm normalized name: adalimumab Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab in combination with azathioprine
Trial: 24710856
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous immunoglobulin (IVIg) maintenance treatment
Trial: 20456838
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese medicine (TCM) treatment (Jiangya Capsule)
Trial: 20456838
Drug: Integrative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrative treatment (Jiangya Capsule plus nimodipine)
Trial: 20456838
Drug: Western medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Western medicine (WM) group (nimodipine plus Jiangya Capsule simulation)
Trial: 17157857
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg DINAC
Trial: 17157857
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg DINAC
Trial: 17157857
Drug: DINAC (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DINAC (both doses)
Trial: 14982314
Drug: Increased cardiovascular
RxNorm normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Increased cardiovascular fitness (on-treatment analysis)
Trial: 11789243
Drug: Lixin Pill
RxNorm normalized name: Prolixin Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixin Pill (LXP)
Trial: 11789243
Drug: LXP plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LXP plus small dosage of digoxin
Trial: 11789243
Drug: Ordinary dosage
RxNorm normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ordinary dosage of digoxin
Trial: 1734794
Drug: Calcium chloride
RxNorm normalized name: Calcium Chloride
DrugBank: Calcium chloride (DB01164)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium chloride (5 mg/kg)
Trial: 27050028
Drug: Omega-3 fatty
RxNorm normalized name: Omega-3 fatty acid
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 fatty acids (O3FAs), n = 65, twice daily for 6 months
Trial: 27050028
Drug: Placebo (olive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (olive oil), n = 65, twice daily for 6 months
Trial: 24841975
Drug: Investigator's choice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigator's choice of one of seven commonly used AML salvage regimens (including high-dose cytarabine, multiagent chemotherapy, hypomethylating agents, hydroxyurea, and supportive care)
Trial: 22749258
Drug: Early initiation
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Early initiation of fingolimod (0.5 mg/d) for 2 years
Trial: 20547017
Drug: HT-group (Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT-group (Estradiol 2 mg + NETA 1 mg)
Trial: 20547017
Drug: HT+C-group (Estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HT+C-group (Estradiol 2 mg + NETA 1 mg + 800 mg clodronate)
Trial: 17878466
Drug: ICS and
RxNorm normalized name: HYPNOTICS AND SEDATIVES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ICS and long-acting beta-agonist combination therapy
Trial: 12197998
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (500 mg ascorbate/d)
Trial: 7772440
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine 1 ml injected into the lumen of the vas deferens
Trial: 7772440
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 1 ml injected into the lumen of the vas deferens
Trial: 6270295
Drug: 1500 mg
RxNorm normalized name: inulin 1500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg of cannabidiol (CBD)
Trial: 31301919
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine 1
Trial: 31301919
Drug: Tdap vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tdap vaccine 2
Trial: 22006379
Drug: High-dose ambroxol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose ambroxol (990 mg/day) for 5 consecutive days after operation